94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC)

• Published in: Journal for immunotherapy of cancer Vol. 9; no. Suppl 2; p. A103
• Main Authors: Chun, Brie, Pucilowska, Joanna, Chang, Shu Ching, Kim, Isaac, Nikitin, Benjamin, Koguchi, Yoshinobu, Redmond, William, Bernard, Brady, Rajamanickam, Venkatesh, Polaske, Nathan, Fields, Paul, Conrad, Valerie, Schmidt, Mark, Urba, Walter, Conlin, Alison, McArthur, Heather, Page, David
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01.11.2021; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Breast cancer; Cancer therapies; Chemotherapy; Clinical trials; Cloning; Immunotherapy; Lymphocytes; Metastasis; Monoclonal antibodies; Regular and Young Investigator Award Abstracts; Targeted cancer therapy

BackgroundPembrolizumab plus curative-intent dose-dense anthracycline-based chemotherapy (ddAC) is associated with improved outcome in PD-L1-negative TNBC,1 whereas in the metastatic setting, clinical benefit of chemoimmunotherapy (taxane or gemcitabine/carboplatin) is restricted to PD-L1-positive p...